Chugai to co-develop diabetes candidate in Japan with Kowa, Sanofi

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) granted Kowa Co. Ltd. (Nagoya, Japan) and Sanofi (Euronext:SAN; NYSE:SNY) rights to co-develop Chugai's diabetes compound CSG452 in Japan. The three partners will co-develop the sodium-glucose cotransporter 2 (SGLT2) inhibitor, and Kowa and Sanofi will be responsible for submitting regulatory applications. Chugai, which will manufacture the product, is eligible for milestones. CSG452 is in Phase III testing in Japan to treat Type II diabetes. ...